GSK latest news: buyback and Orphan Drug boost investor sentiment

Traders Union
All News
Financial News
Gsk rises 0.55% to $1,649 today

Highlights

GSK plc shares trade at $1,649.00 above MA-20, MA-50, and MA-200 levels, signaling bullish technical momentum across all timeframes.
GSK repurchased 166,000 shares on October 27, 2025, totaling 6,448,500 since September, secured Orphan Drug Designation for a B7-H3 ADC, and signed a new respiratory drug license.
In the next five trading days, GSK is projected to range between $1,694.50 and $1,824.77, with over 80% probability of upward movement and mixed technical signals.

Buybacks, drug approvals and licensing sustain positive market sentiment

On October 27, 2025, GSK completed a purchase of 166,000 ordinary shares under its ongoing buyback program, increasing the total repurchased since September to 6,448,500 shares held as treasury. The company also received Orphan Drug Designation from the European Medicines Agency for its B7-H3-targeted antibody-drug conjugate, aimed at treating pulmonary neuroendocrine carcinoma. GSK signed a new international licensing agreement for a respiratory disease treatment, and recent financials report solid underlying free cash flow of about $500 million with profitability in line or ahead of expectations.

Mixed technical signals as momentum indicators diverge near key resistance

From a technical perspective, GSK holds above its primary moving averages, with dynamic support at the Ichimoku Kijun near $1,569.75 and resistance just below the psychological level of $1,650. Momentum indicators are mixed — the MACD remains firmly bullish, while ADX points to a decrease in trend strength on the daily and weekly charts. RSI and CCI show some room for further gains without being overbought on the daily, but the weekly RSI is elevated, suggesting some caution. The Stoch RSI on daily is low but not yet oversold, BBP is neutral, and the Awesome Oscillator does not fully confirm the current uptrend, indicating moderate volatility and mixed signals.

Bullish bias and high probability of sideways consolidation in near term

In the next five trading days, GSK is expected to trade within a range from $1,694.50 to $1,824.77. The probability of a move higher exceeds 80%, with a sideways consolidation between immediate support and resistance the most likely scenario. A bullish breakout above $1,650 could target weekly highs, while a drop below support at $1,569.75 may trigger a correction towards the MA-20 or MA-50.

Anton Kharitonov, expert at Traders Union, sees GSK maintaining bullish technical posture above core moving averages, yet he notes the mixed nature of momentum signals and elevated weekly RSI as reasons for caution. The analyst acknowledges positive fundamental drivers—including share buybacks, drug designations, and resilient cash flow—but highlights that technical signals do not confirm a strong trend continuation. In his view, the most probable short-term scenario is sideways consolidation rather than an impulsive breakout. "Until GSK can firmly clear $1,650 with decisive momentum, my stance remains defensive—there’s more evidence needed before trusting further upside," Kharitonov concludes.

Previously it was noted that buyback activity and investor accumulation were offset by R&D pipeline risks, with references to volatility remaining low as the price consolidated in a narrow daily range. The technical outlook signaled mixed momentum amid cautious sentiment driven by product developments and regulatory concerns.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.